Company · implicit-bioscience-57e7e6c2
Trials12
The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.
1 to 12 of 12
Download this page as JSON| Trial | Title | Role | Phase | Status | Type | Participants | Start | Results first posted | Drugs | In Trials | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06678074 | Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI | Lead sponsor | Phase 1/2 | Active, not recruiting | Interventional | 10 | 2025-02-06 | IC14 | https://conductscience.org/library/trials/NCT06678074 | ClinicalTrials.gov | |
| NCT06556810 | IC14 for Treatment of Acute Decompensated Heart Failure | Lead sponsor | Phase 1/2 | Active, not recruiting | Interventional | 10 | 2024-10-17 | IC14 | https://conductscience.org/library/trials/NCT06556810 | ClinicalTrials.gov | |
| NCT06513949 | Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients | Lead sponsor | Phase 2 | Recruiting | Interventional | 56 | 2026-06-17 | IC14 | https://conductscience.org/library/trials/NCT06513949 | ClinicalTrials.gov | |
| NCT06275893 | IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy | Lead sponsor | Phase 1/2 | Completed | Interventional | 1 | 2024-03-29 | IC14 | https://conductscience.org/library/trials/NCT06275893 | ClinicalTrials.gov | |
| NCT04391309 | COVID-19 and Anti-CD14 Treatment Trial | Collaborator | Phase 2 | Terminated | Interventional | 49 | 2021-04-12 | 2023-06-15 | REMDESIVIR | https://conductscience.org/library/trials/NCT04391309 | ClinicalTrials.gov |
| NCT04346277 | Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19) | Lead sponsor | No longer available | Expanded access | IC14 | https://conductscience.org/library/trials/NCT04346277 | ClinicalTrials.gov | ||||
| NCT04309604 | IC14 for ALS Patients Expanded Access | Lead sponsor | No longer available | Expanded access | IC14 | https://conductscience.org/library/trials/NCT04309604 | ClinicalTrials.gov | ||||
| NCT03875560 | IC14 in Adult Patients With Dengue Fever | Lead sponsor | Phase 2 | Withdrawn | Interventional | 0 | 2019-05 | IC14 | https://conductscience.org/library/trials/NCT03875560 | ClinicalTrials.gov | |
| NCT03508453 | IC14 for Treatment of Amyotrophic Lateral Sclerosis | Lead sponsor | Phase 2 | Withdrawn | Interventional | 0 | 2021-08-15 | IC14 | https://conductscience.org/library/trials/NCT03508453 | ClinicalTrials.gov | |
| NCT03487263 | Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease | Lead sponsor | Phase 1 | Completed | Interventional | 10 | 2017-10-01 | IC14 | https://conductscience.org/library/trials/NCT03487263 | ClinicalTrials.gov | |
| NCT03474263 | IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS) | Lead sponsor | Phase 2 | Withdrawn | Interventional | 0 | 2019-09-01 | IC14 | https://conductscience.org/library/trials/NCT03474263 | ClinicalTrials.gov | |
| NCT03017547 | A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome | Lead sponsor | Phase 2 | Withdrawn | Interventional | 0 | 2019-06 | IC14 | https://conductscience.org/library/trials/NCT03017547 | ClinicalTrials.gov |
companies-2026-11-14-0.1.0
Sources 4
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL
- ClinicalTrials.govNo license stated
- Open TargetsCC0 1.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/companies/v1/implicit-bioscience-57e7e6c2/trials